NCT04847050
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with a history of leptomeningeal disease; Patients with a known history of the SARS-CoV-2 infection; Patients who have received an investigational coronavirus (e.g., SARS-CoV-2, SARS-CoV, MERS-CoV vaccine)
https://ClinicalTrials.gov/show/NCT04847050